In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study aimed to investigate the safety and risk of disease recurrence in breast cancer survivors who were treated with systemic (whole-body) hormone replacement therapy (HRT). This study concluded that use of HRT increased the risk of disease recurrence in these patients. Some background Some breast...
Read More
Each year in the United States, approximately 264,000 women and 2,400 men are diagnosed with breast cancer. Of those people, about 30% will go on to develop metastatic breast cancer (cancer that has spread beyond the breast, often to the brain, lungs, bones, or liver). Biopsies of breast cancer tissue determine if the surface of the cancer cells...
Read More
In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC). This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...
Read More
In a nutshell This study compared the effectiveness of aromatase inhibitors (AIs) versus tamoxifen (Nolvadex) for the treatment of premenopausal patients with estrogen receptor-positive (ER+) early-stage breast cancer (BC) treated with ovarian suppression. The data showed that AIs significantly reduced the risk of BC recurrence compared...
Read More
In a nutshell The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers. Some background The main treatment for early...
Read More
In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...
Read More
In a nutshell This study evaluated the effectiveness of antiresorptive drugs on bone mineral density (BMD) in postmenopausal women with early-stage breast cancer (BC) receiving treatment with aromatase inhibitors (AIs). The data showed that denosumab (Prolia) and zoledronic acid (Aclasta) were the most effective antiresorptive treatment options to...
Read More
In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...
Read More
In a nutshell This study aimed to investigate the oncological effectiveness of intraoperative radiotherapy (IORT) and whole breast irradiation (WBI) for patients with early breast cancer (BC). This study concluded that there was a high oncological effectiveness for both groups of patients. Some background Intraoperative...
Read More
In a nutshell This study compared the effectiveness and safety of trastuzumab emtansine (T-DM1; Kadcyla) plus pertuzumab (Perjeta) versus taxanes plus trastuzumab (Herceptin) plus pertuzumab (THP) in patients with high-risk HER2-positive (+) early breast cancer (BC) after previous treatment with anthracycline-based chemotherapy. The data showed that...
Read More
